Tracheal atypical solitary carcinoid in a so called “difficult asthma”: a diagnostic challenge

Submitted: March 27, 2023
Accepted: July 23, 2023
Published: August 2, 2023
Abstract Views: 333
PDF_early view: 246
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

This report describes the case of a 46-year-old non-smoker housewife. She presented to our attention having a diagnosis of “difficult asthma” from another center in the previous two years. She had no allergies and had not been exposed to an excessive amount of noxious stimuli. Her chronic respiratory symptoms (dyspnea on exertion with wheezing) remained uncontrolled despite maximal anti-asthmatic inhaled therapy. An HRCT scan was performed to further investigate other pulmonary diseases that mimic asthma. It revealed a pedunculated endotracheal lesion with regular borders that obstructed 90% of the tracheal lumen. The lesion was removed via rigid bronchoscopy with laser endobronchial; histological examination revealed the presence of atypical carcinoid. Atypical carcinoids are a rare subtype of neuroendocrine lung tumor that accounts for 2% of all thoracic malignancies. They frequently arise from the central airways and cause obstructive symptoms such as coughing, wheezing, chest pain, or recurrent obstructing pneumonia, which is caused by central airway obstruction. Clinical onset is gradual and characterized by non-specific symptoms, which frequently result in misdiagnosis. As a result, in a young patient with progressive dyspnea, chronic cough, and wheezing that is not responding to anti-asthmatic treatment, second-level investigations are required and may lead to a definite diagnosis, allowing the appropriate course of treatment to begin.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Boissière L, Patey M, Toubas O, et al. Tracheobronchial involvement of rosai-dorfman disease: case report and review of the literature. Medicine (Baltimore) 2016;95:e2821. DOI: https://doi.org/10.1097/MD.0000000000002821
Caplin ME, Baudin E, Ferolla P, et al. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol 2015;26:1604-20. DOI: https://doi.org/10.1093/annonc/mdv041
Macchiarini P. Primary tracheal tumours. Lancet Oncol 2006;7:83-91. DOI: https://doi.org/10.1016/S1470-2045(05)70541-6
Berliner D, Schneider N, Welte T, Bauersachs J. The differential diagnosis of dyspnea. Dtsch Arztebl Int 2016;113:834-45. DOI: https://doi.org/10.3238/arztebl.2016.0834
Koch A, Behr J. [Cough and its differential diagnosis].[Article in German]. Dtsch Med Wochenschr 2018;143:1258-71. DOI: https://doi.org/10.1055/s-0043-109521
Ewert R, Gläser S. [Dyspnea. From the concept up to diagnostics].[Article in German]. Internist (Berl) 2015;56:865-71. DOI: https://doi.org/10.1007/s00108-015-3690-3
Rekhtman N. Lung neuroendocrine neoplasms: recent progress and persistent challenges. Mod Pathol 2022;35:S36-50. DOI: https://doi.org/10.1038/s41379-021-00943-2
Rindi G, Mete O, Uccella S, et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr Pathol 2022;33:115-54. DOI: https://doi.org/10.1007/s12022-022-09708-2
Melosky B. Advanced typical and atypical carcinoid tumours of the lung: management recommendations. Curr Oncol 2018;25:S86S93. DOI: https://doi.org/10.3747/co.25.3808
Hendifar AE, Marchevsky AM, Tuli R. Neuroendocrine tumors of the lung: current challenges and advances in the diagnosis and management of well-differentiated disease. J Thorac Oncol 2017;12:425-36 DOI: https://doi.org/10.1016/j.jtho.2016.11.2222
Wolin EM. Challenges in the diagnosis and management of well-differentiated neuroendocrine tumors of the lung (typical and atypical carcinoid): current status and future considerations. Oncologist 2015;20:1123-31. DOI: https://doi.org/10.1634/theoncologist.2015-0198
Raz DJ, Nelson RA, Grannis FW, Kim JY. Natural history of typical pulmonary carcinoid tumors: a comparison of nonsurgical and surgical treatment. Chest 2015;147:1111-7. DOI: https://doi.org/10.1378/chest.14-1960
Baudin E, Caplin M, Garcia-Carbonero R, et al. Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆. Ann Oncol 2021;32:439-51. Erratum in: Ann Oncol 2021;32:1453-5. DOI: https://doi.org/10.1016/j.annonc.2021.08.2150
Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med 2017;376:125-35. DOI: https://doi.org/10.1056/NEJMoa1607427
Batra H, Yarmus L. Indications and complications of rigid bronchoscopy. Expert Rev Respir Med 2018;12:509-20. DOI: https://doi.org/10.1080/17476348.2018.1473037

How to Cite

Turrin, Martina, Francesca Maria Pontoriero, Giordano Fiorentù, Giulia Grisostomi, Francesca Zampieri, Francesca Savoia, Cosimo Catino, Giuseppe Zanardi, Piera Peditto, Nicola Malacchini, Fabiola Zeraj, Matteo Bonato, Diana Sacchi, Maria Guido, Giovanni Morana, and Micaela Romagnoli. 2023. “Tracheal Atypical Solitary Carcinoid in a so Called ‘difficult asthma’: A Diagnostic Challenge”. Monaldi Archives for Chest Disease, August. https://doi.org/10.4081/monaldi.2023.2586.